NASDAQ:SVA - Sinovac Biotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.70 +0.04 (+0.52 %)
(As of 07/20/2018 09:59 AM ET)
Previous Close$7.66
Today's Range$7.70 - $7.70
52-Week Range$6.50 - $8.75
Volume30 shs
Average Volume27,500 shs
Market Capitalization$439.05 million
P/E RatioN/A
Dividend YieldN/A
Sinovac Biotech logoSinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against enterovirus71 (EV710), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and split viron pandemic influenza vaccine. The company also completed phase III clinical trials for EV71, varicella, and pneumococcal polysaccharide vaccines. In addition, it has completed pre-clinical studies for sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate, Quadrivalent influenza, and rubella vaccines. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.08
Current Ratio2.20
Quick Ratio1.99


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.35 million
Price / Sales2.52
Cash Flow$0.5106 per share
Price / Cash15.08
Book Value$3.11 per share
Price / Book2.48


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares57,020,000
Market Cap$439.05

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

How were Sinovac Biotech's earnings last quarter?

Sinovac Biotech Ltd. (NASDAQ:SVA) released its earnings results on Tuesday, August, 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The biopharmaceutical company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $18.49 billion. During the same period in the prior year, the firm earned $0.02 earnings per share. View Sinovac Biotech's Earnings History.

What is the consensus analysts' recommendation for Sinovac Biotech?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sinovac Biotech in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Sinovac Biotech's key competitors?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:
  • Mr. Ming Xia, VP of Sales & Marketing (Age 44)
  • Dr. Weidong Yin, Chairman, Pres, CEO, MD & Sec. (Age 53)
  • Ms. Nan Wang, CFO & VP of Bus. Devel. (Age 52)
  • Mr. Gao Qiang, VP of R&D (Age 41)
  • Ms. Li Jing, VP of Quality & Production (Age 43)

Has Sinovac Biotech been receiving favorable news coverage?

News coverage about SVA stock has trended somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.14 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Sinovac Biotech?

Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $7.70.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $439.05 million and generates $174.35 million in revenue each year. Sinovac Biotech employs 724 workers across the globe.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 100085. The biopharmaceutical company can be reached via phone at 86-10-8289-0088 or via email at [email protected]

MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.